For the generics, especially, yes. It's to a limited extent when it comes to single-source products that are of equal benefit.
On May 2nd, 2017. See this statement in context.
On May 2nd, 2017. See this statement in context.
May 2nd, 2017 / 1:05 p.m.
Senior Policy Advisor on Pricing and Reimbursement of Pharmaceuticals, Department of Pharmaceutical Affairs and Medical Technology, Dutch Ministry of Health, Welfare and Sports
For the generics, especially, yes. It's to a limited extent when it comes to single-source products that are of equal benefit.
See context to find out what was said next.